Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8241586 | 1.00 | ELANE (0.40) | ELANEKLK5DPP8DPP4DPP9 | |
| SCHEMBL2743892 | 0.90 | KLK5 (0.34) | ELANEKLK5CTSLCTSKAAK1 | |
| SCHEMBL13594519 | 0.90 | DPP8 (0.37) | ELANEDPP8DPP4DPP9DPP7 | |
| SCHEMBL4458000 | 0.90 | DPP8 (0.37) | ELANEDPP8DPP4DPP9DPP7 | |
| SCHEMBL4408069 | 0.86 | ELANE (0.52) | ELANEKLK5NAMPTCTSK | |
| SCHEMBL13594509 | 0.86 | ELANE (0.52) | ELANEKLK5NAMPTCTSK | |
| SCHEMBL8236821 | 0.85 | ELANE (0.42) | ELANECTSLNAMPTCTSKDRD2 | |
| SCHEMBL13594377 | 0.85 | ELANE (0.41) | ELANECTSLNAMPTCTSKDRD2 | |
| SCHEMBL13594513 | 0.84 | NAMPT (0.37) | KLK5DPP8DPP4DPP9DPP7 | |
| SCHEMBL8236830 | 0.84 | ELANE (0.36) | ELANEDPP8DPP4DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090304631-A1 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PHENOMIX CORPORATION | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090304631-A1 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PREP, CTSC, PEPD | ELANE 208/4885KLK5 413/4885DPP8 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.